# Analytical Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/analytical-biosciences

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.abiosciences.com
- Latest round: Series A (May 25, 2021)
- Investors on record: 6

## About

Based in Beijing, China and established in 2018, Analytical Biosciences Limited is a single-cell genome developer which focuses on single cell sequencing and map researches, cancer genomics, bioinformatics and biological big data mining. In December 2020, Analytical Biosciences Limited raised an undisclosed amount of series A+ l funding ledy new investor Softbank China Venture Capital	and followed by new investor Apricot Capital and returning investor IDG Capital. The company has established dual operation centers in China and the United States.

The company is committed to fully applying the single-cell mechanism research platform and bioinformatics big data/AI platform to the treatment and diagnosis of major human diseases such as cancer. Through the established and high-speed and continuous improvement of the single-cell accurate map of human diseases, new ones can be discovered Targets for treatment and diagnosis, and produce breakthrough therapeutic drugs.
The company will further systematically expand and accelerate the company’s single-cell big data platform, single-cell one-stop data analysis platform and other transformational applications in the field of innovative drug research and development; strengthen the company’s drug target research and development center, candidate macromolecular mechanism research and development center and high performance The construction of the biological computing/AI platform enhances the company's core competitiveness in the efficient processing and in-depth interpretation of massive single-cell data. At the same time, the company will also promote the development of new drug targets, biological immunological verification, antibody development, biomarker discovery, basic scientific research and clinical research.

## Funding rounds

- Series A, May 25, 2021 — Hong Shan, IDG Capital, Green Pine Capital Partners, Primavera Capital Group
- Series A, Dec 29, 2020 — SB China Venture Capital, IDG Capital, Apricot Capital
- Series A, Jun 27, 2019 — IDG Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Hong Shan — Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series A